Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Loperamide step-down plus bifidobacterium for prevention of anastomotic leakage after left-sided colorectal cancer surgery
ChiCTR2600131446Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Oct 2026
- Modality
- Small Molecules, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of loperamide and Golden Bifid in anastomotic dehiscence (AD), sponsored by West China Hospital of Sichuan University. Primary endpoint: Incidence of clinical anastomotic leakage within 30 postoperative days. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
loperamideGolden Bifid
03
Conditions
anastomotic dehiscence (AD)
Beyond the preview
Go deeper on ChiCTR2600131446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600131446.